Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Department of Biology, Slippery Rock University of Pennsylvania, Slippery Rock, PA 16057, USA.
Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Neurobiol Dis. 2021 May;152:105299. doi: 10.1016/j.nbd.2021.105299. Epub 2021 Feb 15.
Triosephosphate isomerase (TPI) deficiency (Df) is a rare recessive metabolic disorder that manifests as hemolytic anemia, locomotor impairment, and progressive neurodegeneration. Research suggests that TPI Df mutations, including the "common" TPImutation, result in reduced TPI protein stability that appears to underlie disease pathogenesis. Drosophila with the recessive TPI allele (a.k.a. sgk or M81T) exhibit progressive locomotor impairment, neuromuscular impairment and reduced longevity, modeling the human disorder. TPI produces a functional protein that is degraded by the proteasome. Molecular chaperones, such as Hsp70 and Hsp90, have been shown to contribute to the regulation of TPI degradation. In addition, stabilizing the mutant protein through chaperone modulation results in improved TPI deficiency phenotypes. To identify additional regulators of TPI degradation, we performed a genome-wide RNAi screen that targeted known and predicted quality control proteins in the cell to identify novel factors that modulate TPI turnover. Of the 430 proteins screened, 25 regulators of TPI were identified. Interestingly, 10 proteins identified were novel, previously undescribed Drosophila proteins. Proteins involved in co-translational protein quality control and ribosome function were also isolated in the screen, suggesting that TPI may undergo co-translational selection for polyubiquitination and proteasomal degradation as a nascent polypeptide. The proteins identified in this study may reveal novel pathways for the degradation of a functional, cytosolic protein by the ubiquitin proteasome system and define therapeutic pathways for TPI Df and other biomedically important diseases.
磷酸丙糖异构酶(TPI)缺乏症(Df)是一种罕见的隐性代谢紊乱,表现为溶血性贫血、运动障碍和进行性神经退行性变。研究表明,TPI Df 突变,包括“常见”的 TPImutation,导致 TPI 蛋白稳定性降低,这似乎是疾病发病机制的基础。具有隐性 TPI 等位基因(又名 sgk 或 M81T)的果蝇表现出进行性运动障碍、神经肌肉障碍和寿命缩短,模拟了人类疾病。TPI 产生一种功能性蛋白质,该蛋白质被蛋白酶体降解。分子伴侣,如 Hsp70 和 Hsp90,已被证明有助于 TPI 降解的调节。此外,通过伴侣蛋白调节稳定突变蛋白会导致 TPI 缺乏表型的改善。为了鉴定 TPI 降解的其他调节剂,我们进行了全基因组 RNAi 筛选,该筛选针对细胞中已知和预测的质量控制蛋白,以鉴定调节 TPI 周转率的新因子。在筛选的 430 种蛋白质中,有 25 种 TPI 调节剂被鉴定出来。有趣的是,鉴定出的 10 种蛋白质是新的、以前未描述的果蝇蛋白质。在筛选中还分离到涉及共翻译蛋白质质量控制和核糖体功能的蛋白质,这表明 TPI 可能在翻译过程中经历多泛素化和蛋白酶体降解的共翻译选择,作为新生多肽。本研究中鉴定的蛋白质可能揭示了一种功能性胞质蛋白通过泛素蛋白酶体系统降解的新途径,并为 TPI Df 和其他具有重要生物医学意义的疾病定义了治疗途径。